StockNews.com Upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Strong-Buy

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a strong-buy rating in a research note published on Sunday morning.

Separately, Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $31.26 on Friday. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of 29.22 and a beta of 0.83. Supernus Pharmaceuticals has a 1 year low of $25.53 and a 1 year high of $40.28. The firm’s 50 day moving average price is $36.22 and its two-hundred day moving average price is $35.17.

Insider Buying and Selling

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. This represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,104 shares of company stock valued at $440,263. Company insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors have recently modified their holdings of SUPN. Pacer Advisors Inc. boosted its stake in shares of Supernus Pharmaceuticals by 29.9% during the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after buying an additional 403,028 shares during the period. Woodline Partners LP boosted its stake in shares of Supernus Pharmaceuticals by 124.8% during the 4th quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company’s stock valued at $15,326,000 after buying an additional 235,257 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Supernus Pharmaceuticals by 248.0% during the 4th quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company’s stock valued at $10,581,000 after buying an additional 208,552 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at $6,847,000. Finally, Great Lakes Advisors LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at $6,131,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.